Categories
Uncategorized

Sinopharm Updates

February 25, 2021: The National Medical Products Administration in China has approved use of a second COVID-19 vaccine developed by Sinopharm. This is an inactivated vaccine developed in collaboration with the Wuhan Institute of Biologics. Sinopharm reported that the vaccine is 72.51% effective. However, no data from the Phase 3 studies evaluating this vaccine have been released to the public and no study findings have been published in the peer-reviewed scientific literature. Therefore, it is not possible to determine whether this estimate of vaccine efficacy is valid or reliable.

January 2, 2021: The National Medical Products Administration in China has approved use of a COVID-19 vaccine developed by Sinopharm. This is an inactivated vaccine developed in collaboration with the Beijing Institute of Biological Products. Sinopharm reported that the vaccine is 86% effective in preventing all cases of COVID-19 and 100% effective in preventing moderate and severe cases. It is not clear if asymptomatic cases were included in the analyses or if symptomatic cases needed to be confirmed by laboratory testing.  In previous reports, the vaccine was reported to be 79.34% effective. The Company stated that the discrepancy between the two estimates was due to differences in study methods used in different countries. Unfortunately, no data from the Phase 3 studies evaluating this vaccine have been released to the public and no study findings have been published in the peer-reviewed scientific literature. Therefore, it is not possible to determine whether the estimates of vaccine efficacy are valid or reliable.